On June 23, RemeGen rose 5.02% in regular trading, trading at HKD 68.3/share, with turnover of HKD 117 million.

On the news front, the Hong Kong biotech sector staged a collective rebound following a sharp selloff in the prior session. Peers including CStone Pharmaceuticals and康诺亚 rose 7%, Akeso gained 4.28%, and Innovent Biologics added 3.19%, signaling a clear recovery in sector sentiment. On June 22, the broader sector had been under sustained selling pressure due to concerns over Fed rate hike expectations and BD licensing uncertainties.

Additionally, RemeGen announced on June 22 that 193 million first-offering restricted shares, representing 34.16% of total share capital, will become tradeable on July 1. However, because the company has not met cash dividend distribution requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing their A-share holdings via centralized bidding or block trading. This regulatory restriction substantially mitigates actual selling pressure expectations, alleviating market concerns over the lock-up expiry impact.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)